IRCT20210715051901N1
Recruiting
Phase 3
The effect of Atomoxetine on Cognitive Function of Inpatient and Outpatient Multiple Sclerosis
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis.
- Sponsor
- Ahvaz University of Medical Sciences
- Enrollment
- 52
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of Multiple Sclerosis based on McDonald's criteria
- •Age between 18 to 55 years
- •Testable Measurable Cognitive impairment (MACFIMS) attributed to Multiple Sclerosis
Exclusion Criteria
- •Continued use of Stimulant
- •Clinical relapse of Multiple Sclerosis with in 60 days of screening
- •Changes in the treatment of Multiple Sclerosis within 90 days of screening
- •Existence of any underlying factor and disease that causes dementia and cognitive impairment
- •Proof of moderate to severe depression with a Beck's test
- •Contraindications to the use of Atomoxetine
- •Confirmation of cognitive impairment related to Multiple Sclerosis with McFimes test
Outcomes
Primary Outcomes
Not specified
Similar Trials
Suspended
Not Applicable
Effects of atomoxetine on cognitive functions in normal subjects using fMRIHealthy adultsJPRN-UMIN000012947ippon Medical School25
Recruiting
Phase 3
The Effect of Atomoxetine on Cognitive Symptoms in Schizophrenia PatientsIRCT20211219053452N1Arak University of Medical Sciences40
Recruiting
Phase 2
Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophreniaIRCT20101130005280N31Mashhad University of Medical Sciences42
Not yet recruiting
Phase 3
Atomoxetine for cognitive impairment in Behcet's diseaseIRCT20211206053288N1Tehran University of Medical Sciences40
Completed
Phase 3
Study of therapeutic effects of Atomoxtein in reducing the symptoms of patients with recurrent vasovagal syncopeIRCT20180125038507N1Tehran University of Medical Sciences50